Predictive and prognostic factors for gliomas

References

• Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352(10), 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol.114(2), 97–109 (2007).
   PubMed Web of Science ®Google Scholar
• He J, Mokhtari K, Sanson M et al. Glioblastomas with an oligodendroglial component: a pathological and molecular study. J. Neuropathol. Exp. Neurol.60(9), 863–871 (2001).
   PubMed Web of Science ®Google Scholar
• Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer79(7), 1381–1393 (1997).
   PubMed Web of Science ®Google Scholar
• Verhaak RG, Hoadley KA, Purdom E et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell17(1), 98–110 (2010).
   PubMed Web of Science ®Google Scholar
• Noushmehr H, Weisenberger DJ, Diefes K et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell17(5), 510–522 (2010).
   PubMed Web of Science ®Google Scholar
• Bromberg JE, van den Bent MJ. Oligodendrogliomas: molecular biology and treatment. Oncologist14(2), 155–163 (2009).
   PubMedGoogle Scholar
• Jenkins RB, Blair H, Ballman KV et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res.66(20), 9852–9861 (2006).
   PubMed Web of Science ®Google Scholar
• Cairncross JG, Ueki K, Zlatescu MC et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl Cancer Inst.90(19), 1473–1479 (1998).
   PubMed Web of Science ®Google Scholar
• Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am. J. Pathol.145(5), 1175–1190 (1994).
   PubMed Web of Science ®Google Scholar
• Bauman GS, Ino Y, Ueki K et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int. J. Radiat. Oncol. Biol. Phys.48(3), 825–830 (2000).
   PubMed Web of Science ®Google Scholar
• Cairncross G, Berkey B, Shaw E et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J. Clin. Oncol.24(18), 2707–2714 (2006).
   PubMed Web of Science ®Google Scholar
• Kaloshi G, Everhard S, Laigle-Donadey F et al. Genetic markers predictive of chemosensitivity and outcome in gliomatosis cerebri. Neurology70(8), 590–595 (2008).
   PubMedGoogle Scholar
• van den Bent MJ, Carpentier AF, Brandes AA et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer Phase III trial. J. Clin. Oncol.24(18), 2715–2722 (2006).
   PubMed Web of Science ®Google Scholar
• Weller M, Berger H, Hartmann C et al. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin. Cancer Res.13(23), 6933–6937 (2007).
   PubMed Web of Science ®Google Scholar
• Ricard D, Kaloshi G, Amiel-Benouaich A et al. Dynamic history of low-grade gliomas before and after temozolomide treatment. Ann. Neurol.61(5), 484–490 (2007).
   PubMedGoogle Scholar
• Ducray F, El Hallani S, Idbaih A. Diagnostic and prognostic markers in gliomas. Curr. Opin. Oncol.21(6), 537–542 (2009).
   PubMedGoogle Scholar
• Ichimura K, Vogazianou AP, Liu L et al. 1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas. Oncogene27(14), 2097–2108 (2008).
   PubMed Web of Science ®Google Scholar
• Idbaih A, Marie Y, Pierron G et al. Two types of chromosome 1p losses with opposite significance in gliomas. Ann. Neurol.58(3), 483–487 (2005).
   PubMedGoogle Scholar
• Griffin CA, Burger P, Morsberger L et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J. Neuropathol. Exp. Neurol.65(10), 988–994 (2006).
   PubMed Web of Science ®Google Scholar
• Benetkiewicz M, Idbaih A, Cousin PY et al. NOTCH2 is neither rearranged nor mutated in t(1;19) positive oligodendrogliomas. PLoS One4(1), e4107 (2009).
   PubMedGoogle Scholar
• Idbaih A, Criniere E, Marie Y et al. Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomas. Neuro. Oncol.10(4), 540–547 (2008).
   PubMedGoogle Scholar
• Idbaih A, Marie Y, Lucchesi C et al. BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. Int. J. Cancer122(8), 1778–1786 (2008).
   PubMedGoogle Scholar
• Brandes AA, Tosoni A, Cavallo G et al. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J. Clin. Oncol.24(29), 4746–4753 (2006).
   PubMed Web of Science ®Google Scholar
• Mollemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int. J. Cancer113(3), 379–385 (2005).
   PubMed Web of Science ®Google Scholar
• Ducray F, Idbaih A, de Reynies A et al. Anaplastic oligodendrogliomas with 1p/19q codeletion have a proneural gene expression profile. Mol. Cancer7, 41 (2008).
   PubMedGoogle Scholar
• Phillips HS, Kharbanda S, Chen R et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell9(3), 157–173 (2006).
   PubMed Web of Science ®Google Scholar
• Ducray F, Criniere E, Idbaih A et al. α-Internexin expression identifies 1p/19q codeleted gliomas. Neurology72(2), 156–161 (2009).
   PubMedGoogle Scholar
• Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med.352(10), 997–1003 (2005).
   PubMed Web of Science ®Google Scholar
• Esteller M, Garcia-Foncillas J, Andion E et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med.343(19), 1350–1354 (2000).
   PubMed Web of Science ®Google Scholar
• Karayan-Tapon L, Quillien V, Guilhot J et al. Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J. Neurooncol.97(3), 311–322 (2009).
   PubMedGoogle Scholar
• Rivera AL, Pelloski CE, Gilbert MR et al. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro. Oncol.12(2), 116–121 (2010).
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol.10(5), 459–466 (2009).
   PubMed Web of Science ®Google Scholar
• Glas M, Happold C, Rieger J et al. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J. Clin. Oncol.27(8), 1257–1261 (2009).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Dubbink HJ, Sanson M et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J. Clin. Oncol.27(35), 5881–5886 (2009).
   PubMed Web of Science ®Google Scholar
• Wick W, Hartmann C, Engel C et al. NOA-04 randomized Phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J. Clin. Oncol.27(35), 5874–5880 (2009).
   PubMed Web of Science ®Google Scholar
• Ducray F, Del Rio MS, Carpentier C et al. Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma. J. Neurooncol.101(3), 457–462 (2011).
   PubMedGoogle Scholar
• Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J. Clin. Oncol.26(13), 2192–2197 (2008).
   PubMed Web of Science ®Google Scholar
• Everhard S, Kaloshi G, Criniere E et al. MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann. Neurol.60(6), 740–743 (2006).
   PubMed Web of Science ®Google Scholar
• Everhard S, Tost J, El Abdalaoui H et al. Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro. Oncol.11(4), 348–356 (2009).
   PubMed Web of Science ®Google Scholar
• Parsons DW, Jones S, Zhang X et al. An integrated genomic analysis of human glioblastoma multiforme. Science321(5897), 1807–1812 (2008).
   PubMed Web of Science ®Google Scholar
• Kang MR, Kim MS, Oh JE et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int. J. Cancer125(2), 353–355 (2009).
   PubMed Web of Science ®Google Scholar
• Yan H, Parsons DW, Jin G et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med.360(8), 765–773 (2009).
   PubMed Web of Science ®Google Scholar
• Sanson M, Marie Y, Paris S et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J. Clin. Oncol.27(25), 4150–4154 (2009).
   PubMed Web of Science ®Google Scholar
• Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin. Cancer Res.15(19), 6002–6007 (2009).
   PubMed Web of Science ®Google Scholar
• Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am. J. Pathol.174(4), 1149–1153 (2009).
   PubMed Web of Science ®Google Scholar
• Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol.116(6), 597–602 (2008).
   PubMed Web of Science ®Google Scholar
• Bleeker FE, Lamba S, Leenstra S et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum. Mutat.30(1), 7–11 (2009).
   PubMed Web of Science ®Google Scholar
• Mardis ER, Ding L, Dooling DJ et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med.361(11), 1058–1066 (2009).
   PubMed Web of Science ®Google Scholar
• Marcucci G, Maharry K, Wu YZ et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J. Clin. Oncol.28(14), 2348–2355 (2010).
   PubMed Web of Science ®Google Scholar
• Ward PS, Patel J, Wise DR et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell17(3), 225–234 (2010).
   PubMed Web of Science ®Google Scholar
• Hartmann C, Meyer J, Balss J et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol.118(4), 469–474 (2009).
   PubMed Web of Science ®Google Scholar
• Labussiere M, Idbaih A, Wang XW et al. All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology74(23), 1886–1890 (2010).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Dubbink HJ, Marie Y et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin. Cancer Res.16(5), 1597–1604 (2010).
   PubMed Web of Science ®Google Scholar
• Dubbink HJ, Taal W, van Marion R et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology73(21), 1792–1795 (2009).
   PubMed Web of Science ®Google Scholar
• Houillier C, Wang X, Kaloshi G, Delattre JY. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology75(17), 1560–1566 (2010).
   PubMed Web of Science ®Google Scholar
• Ichimura K, Pearson DM, Kocialkowski S et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro. Oncol.11(4), 341–347 (2009).
   PubMed Web of Science ®Google Scholar
• Zhao S, Lin Y, Xu W et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α. Science324(5924), 261–265 (2009).
   PubMed Web of Science ®Google Scholar
• Dang L, White DW, Gross S et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature462(7274), 739–744 (2009).
   PubMed Web of Science ®Google Scholar
• Aghili M, Zahedi F, Rafiee E. Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review. J. Neurooncol.91(2), 233–236 (2009).
   PubMedGoogle Scholar
• Latini A, Scussiato K, Rosa RB et al.D-2-hydroxyglutaric acid induces oxidative stress in cerebral cortex of young rats. Eur. J. Neurosci.17(10), 2017–2022 (2003).
   PubMed Web of Science ®Google Scholar
• Ducray F, Marie Y, Sanson M. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med.360(21), 2248; author reply 2249 (2009).
   PubMedGoogle Scholar
• Capper D, Weissert S, Balss J et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol.20(1), 245–254 (2009).
   PubMedGoogle Scholar
• Kato Y, Jin G, Kuan CT, McLendon RE, Yan H, Bigner DD. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem. Biophys. Res. Commun.390(3), 547–551 (2009).
   PubMed Web of Science ®Google Scholar
• Gross S, Cairns RA, Minden MD et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med.207(2), 339–344 (2010).
   PubMed Web of Science ®Google Scholar
• Lee Y, Scheck AC, Cloughesy TF et al. Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med. Genomics1, 52 (2008).
   PubMedGoogle Scholar
• Colman H, Zhang L, Sulman EP et al. A multigene predictor of outcome in glioblastoma. Neuro. Oncol.12(1), 49–57 (2010).
   PubMed Web of Science ®Google Scholar
• Gravendeel LA, Kouwenhoven MC, Gevaert O et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res.69(23), 9065–9072 (2009).
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, McLendon RE et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature444(7120), 756–760 (2006).
   PubMed Web of Science ®Google Scholar
• Liu G, Yuan X, Zeng Z et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer5, 67 (2006).
   PubMed Web of Science ®Google Scholar
• Beier D, Rohrl S, Pillai DR et al. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res.68(14), 5706–5715 (2008).
   PubMed Web of Science ®Google Scholar
• Murat A, Migliavacca E, Gorlia T et al. Stem cell-related ‘self-renewal’ signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J. Clin. Oncol.26(18), 3015–3024 (2008).
   PubMed Web of Science ®Google Scholar
• Pallini R, Ricci-Vitiani L, Banna GL et al. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin. Cancer Res.14(24), 8205–8212 (2008).
   PubMed Web of Science ®Google Scholar
• Kelly JJ, Blough MD, Stechishin OD et al. Oligodendroglioma cell lines containing t(1;19)(q10;p10). Neuro. Oncol.12(7), 745–755 (2010).
   PubMedGoogle Scholar
• Mehrian-Shai R, Chen CD, Shi T et al. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc. Natl Acad. Sci. USA104(13), 5563–5568 (2007).
   PubMed Web of Science ®Google Scholar
• Hormigo A, Gu B, Karimi S et al. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin. Cancer Res.12(19), 5698–5704 (2006).
   PubMed Web of Science ®Google Scholar
• Jung CS, Foerch C, Schanzer A et al. Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain130(Pt 12), 3336–3341 (2007).
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell11(1), 83–95 (2007).
   PubMed Web of Science ®Google Scholar